Find Islatravir manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Islatravir, 865363-93-5, Mk-8591, Efda, Islatravir [usan], 2'-deoxy-4'-c-ethynyl-2-fluoroadenosine
Molecular Formula
C12H12FN5O3
Molecular Weight
293.25  g/mol
InChI Key
IKKXOSBHLYMWAE-QRPMWFLTSA-N
FDA UNII
QPQ082R25D

Islatravir
Islatravir is under investigation in clinical trial NCT04233216 (Doravirine/islatravir (DOR/ISL) in Heavily Treatment-experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)).
1 2D Structure

Islatravir

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(2R,3S,5R)-5-(6-amino-2-fluoropurin-9-yl)-2-ethynyl-2-(hydroxymethyl)oxolan-3-ol
2.1.2 InChI
InChI=1S/C12H12FN5O3/c1-2-12(4-19)6(20)3-7(21-12)18-5-15-8-9(14)16-11(13)17-10(8)18/h1,5-7,19-20H,3-4H2,(H2,14,16,17)/t6-,7+,12+/m0/s1
2.1.3 InChI Key
IKKXOSBHLYMWAE-QRPMWFLTSA-N
2.1.4 Canonical SMILES
C#CC1(C(CC(O1)N2C=NC3=C(N=C(N=C32)F)N)O)CO
2.1.5 Isomeric SMILES
C#C[C@]1([C@H](C[C@@H](O1)N2C=NC3=C(N=C(N=C32)F)N)O)CO
2.2 Other Identifiers
2.2.1 UNII
QPQ082R25D
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 2'-deoxy-4'-ethynyl-2-fluoroadenosine

2. Islatravir

3. Mk-8591

4. Mk8591

2.3.2 Depositor-Supplied Synonyms

1. Islatravir

2. 865363-93-5

3. Mk-8591

4. Efda

5. Islatravir [usan]

6. 2'-deoxy-4'-c-ethynyl-2-fluoroadenosine

7. (2r,3s,5r)-5-(6-amino-2-fluoro-9h-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-ol

8. Qpq082r25d

9. Adenosine, 2'-deoxy-4'-c-ethynyl-2-fluoro-

10. Islatravir (usan)

11. E2fda

12. 2'-deoxy-4'-ethynyl-2-fluoroadenosine

13. (2r,3s,5r)-5-(6-amino-2-fluoro-purin-9-yl)-2-ethynyl-2-(hydroxymethyl)tetrahydrofuran-3-ol

14. 2f-eda

15. E2-fda

16. Islatravir [inn]

17. Islatravir Anhydrous

18. 4'ed2fa

19. Mk-8591 (islatravir)

20. Islatravir [who-dd]

21. Unii-qpq082r25d

22. Chembl517231

23. Schembl2528556

24. 4'-e-d2-fa

25. Dtxsid601046407

26. Mk8591

27. Nsc787789

28. Nsc-787789

29. (2r,3s,5r)-5-(6-amino-2-fluoropurin-9-yl)-2-ethynyl-2-(hydroxymethyl)oxolan-3-ol

30. Hy-104012

31. Cs-0023675

32. A51131

33. D11432

34. A848914

35. 2'-deoxy-4'-c-ethynyl-2-fluoroadenosine;mk-8591

36. Q24977417

37. 9h-purin-6-amine, 9-(2-deoxy-4-c-ethynyl-.beta.-d-erythro-pentofuranosyl)-2-fluoro-

2.4 Create Date
2006-04-29
3 Chemical and Physical Properties
Molecular Weight 293.25 g/mol
Molecular Formula C12H12FN5O3
XLogP3-0.6
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count8
Rotatable Bond Count3
Exact Mass293.09241742 g/mol
Monoisotopic Mass293.09241742 g/mol
Topological Polar Surface Area119 Ų
Heavy Atom Count21
Formal Charge0
Complexity459
Isotope Atom Count0
Defined Atom Stereocenter Count3
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Anti-Retroviral Agents

Agents used to treat RETROVIRIDAE INFECTIONS. (See all compounds classified as Anti-Retroviral Agents.)


Antiviral Agents

Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)


Enzyme Inhibitors

Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)


Nucleic Acid Synthesis Inhibitors

Compounds that inhibit cell production of DNA or RNA. (See all compounds classified as Nucleic Acid Synthesis Inhibitors.)


Reverse Transcriptase Inhibitors

Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. (See all compounds classified as Reverse Transcriptase Inhibitors.)


Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty